Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

NEJM Publishes New Global Clinical Trial Findings Showing Potential Power of Investigational Medication to Improve ...

For further information, please contact Professor Dr Felix Ringshausen, [email protected], telephone (0511) 532-3595. The original paper ‘Phase 3 Trial of the DPP1 Inhibitor Brensocatib ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses exc ...

A new phase 3 trial shows that DPP-1 inhibition with brensocatib reduces exacerbations and slows lung function decline in ...

For patients with bronchiectasis, brensocatib leads to a lower annualized rate of pulmonary exacerbations, according to a ...

Brensocatib significantly reduced the rate of pulmonary exacerbations and slowed lung function decline in patients with ...

The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...

Incorporated announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Pope Francis died of a cerebral stroke that put him into a coma, leading to heart failure, the Vatican has announced. The ...